AI-powered multi-target drug discovery collaboration with InveniAI

Shionogi said it had concluded a research collaboration with InveniAI on AI-powered multi-target drug discovery in psycho-neurological disease using AlphaMeld. The release describes AlphaMeld as an AI drug-discovery platform that identifies multiple targets related to a specific disease and the mechanisms for treating those diseases.